{"id":59880,"date":"2025-01-28T09:58:03","date_gmt":"2025-01-28T08:58:03","guid":{"rendered":"https:\/\/www.aiom.it\/?p=59880"},"modified":"2025-01-30T09:59:01","modified_gmt":"2025-01-30T08:59:01","slug":"trastuzumab-pertuzumab-plus-eribulin-or-taxane-as-first-line-chemotherapy-for-human-epidermal-growth-factor-2-positive-locally-advanced-metastatic-breast-cancer-the-randomized-noninferiority-phase-ii","status":"publish","type":"post","link":"https:\/\/www.aiom.it\/en\/trastuzumab-pertuzumab-plus-eribulin-or-taxane-as-first-line-chemotherapy-for-human-epidermal-growth-factor-2-positive-locally-advanced-metastatic-breast-cancer-the-randomized-noninferiority-phase-ii\/","title":{"rendered":"Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced\/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial"},"content":{"rendered":"<p><em>Toshinari Yamashita, Shigehira Saji, Toshimi Takano, Yoichi Naito, Michiko Tsuneizumi, Akiyo Yoshimura, Masato Takahashi, Junji Tsurutani, Tsuguo Iwatani, Masahiro Kitada, Hiroshi Tada, Natsuko Mori, Toru Higuchi, Tsutomu Iwasa, Kazuhiro Araki, Kei Koizumi, Hiroki Hasegawa, Yohei Uchida, Satoshi Morita, Norikazu Masuda <img loading=\"lazy\" decoding=\"async\" class=\"alignright size-medium wp-image-59339\" src=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2024\/12\/jco_2024-224x300.webp\" alt=\"\" width=\"224\" height=\"300\" srcset=\"https:\/\/www.aiom.it\/wp-content\/uploads\/2024\/12\/jco_2024-224x300.webp 224w, https:\/\/www.aiom.it\/wp-content\/uploads\/2024\/12\/jco_2024.webp 531w\" sizes=\"auto, (max-width: 224px) 100vw, 224px\" \/><\/em><\/p>\n<p><em>Journal of Clinical Oncology<\/em>, 2025, Jan. 9<\/p>\n<p style=\"text-align: right;\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39787453\/\">Abstract Link<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Toshinari Yamashita, Shigehira Saji, Toshimi Takano, Yoichi Naito, Michiko Tsuneizumi, Akiyo Yoshimura, Masato Takahashi, Junji Tsurutani, Tsuguo Iwatani, Masahiro Kitada, Hiroshi Tada, Natsuko Mori, Toru Higuchi, Tsutomu Iwasa, Kazuhiro Araki, Kei Koizumi, Hiroki Hasegawa, Yohei Uchida, Satoshi Morita, Norikazu Masuda Journal of Clinical Oncology, 2025, Jan. 9 Abstract Link<\/p>\n","protected":false},"author":11,"featured_media":59343,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[255],"tags":[],"class_list":["post-59880","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articoli-scientifici-en"],"_links":{"self":[{"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/posts\/59880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/comments?post=59880"}],"version-history":[{"count":1,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/posts\/59880\/revisions"}],"predecessor-version":[{"id":59881,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/posts\/59880\/revisions\/59881"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/media\/59343"}],"wp:attachment":[{"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/media?parent=59880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/categories?post=59880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.aiom.it\/en\/wp-json\/wp\/v2\/tags?post=59880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}